Everspin Technologies

MRAM · NASDAQ

$13.21−$0.21 (−1.56%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $13.42

MRAM analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $26.18 (+98.2% upside)

Low: $19.19
Now: $13.21
High: $39.90

Upgrades and downgrades

The latest rating actions, newest first

MRAM analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Maxim Group	Oct 12, 2026	Initiates	Buy	$25.00	10%
Needham	Aug 6, 2026	Maintains	Buy	$18.50 → $19.00	46%
Needham	Apr 30, 2026	Maintains	Buy	$14.00 → $18.50	46%
Needham	Mar 5, 2026	Maintains	Buy	$15.00 → $14.00	46%
Needham	Nov 10, 2025	Maintains	Buy	$8.00 → $10.50	46%

The case for and against

Updated Oct 17, 2026

Bull case

Everspin Technologies is viewed favorably because it is posting consistent operational momentum, with 2Q26 revenue of $18.7MM rising 41.9% Y/Y, non-GAAP gross margin at 54.7%, and non-product revenue surging to $3.4MM on the $40MM Toggle MRAM subcontract. Its outlook is strengthened by expanding strategic demand, including CXL-based MRAM development with a controller IP partner and AMD, plus its first GEO satellite design win with Astro Digital, which broadens the aerospace franchise beyond prior LEO concentration. Management’s progress on UNISYST, high-reliability xSPI, and the Microchip foundry buildout supports a larger addressable market, greater capacity, and more durable revenue optionality across data center, industrial, automotive, and defense end markets.

Bear case

Everspin Technologies is viewed negatively because its core STT-MRAM adoption may remain slow, limiting the company’s ability to scale its differentiated memory platform across industrial, medical, automotive, aerospace, and data center markets. The bear case also points to macro deterioration in industrial demand, higher-than-expected operating expenses, and a slowdown in Toggle sales, all of which could pressure margins and undermine operating leverage. In addition, competitive risk is rising as rivals develop their own MRAM products, threatening share gains and making the 2026, 2027, and 2028 estimate trajectory more vulnerable to downside.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.